Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

info@aumed.cz+420 603 587 701 English

ABOUT COMPANY

Aumed, a.s.About us

AUMED a.s. focused primarily on the development of new immunobiological products. In recent years, the company has registered increased interest, especially by foreign business partners, in alternative medicines that would replace the current massive use of antibiotics. This massive use is harmful to the environment and it is hazardous to food and feed due to residues in the food chain.

The company has its R&D facilities in Roztoky u Prahy. The company also has a workplace in Brno at Karásek 1, Brno – Řečkovice. The workplace in Brno is equipped with clean rooms that meet the requirements for cleanliness classes A, B and C. The building structure, technological background, instrumentation and professional staff allow the use of the workplace in GMP mode. Technological equipment is oriented mainly for work with microbial material and for immunobiological issues in general. It is suitable not only for pharmaceutical production, but also for pharmaceutical research and development, both in-house and for a wide range of contract activities.

Last but not least, the company also cooperates and rationally uses the research capacities of CEITEC MU and the Institute of Virology of the Slovak Academy of Sciences.

provozovna Brno

COMPANY PHILOSOPHY

Our research is primarily aimed at improving the health of the entire population, which is the cornerstone of the society's function.

Excessive use of antibiotics in healthcare has led to the rise of multi-resistant and pan-resistant strains of bacteria. This has created a serious problem in the field of veterinary and human medicine in the fight against infectious diseases. The same problem are residues in foods that have a negative impact on human health, especially negative for the immune system. Today’s interest is mainly in non-antibiotic and non-generic preparations based on bacteriophage probiotics and enzyme therapy.

Research and subsequent implementation in these areas would reduce the waste burden on the environment, have a positive impact on regional growth and create new jobs with the possibility of involving university students.

RESEARCH PROJECTS

ENZYMES

Development of new enzymatic preparations for the treatment of the most common causative agents of acute and chronic bacterial skin and subcutaneous diseases.

WHOOPING COUGH

Development of a completely new generation of pertussis vaccine with significantly improved performance properties.

TRANSFER FACTOR

Research and development of transfer factors intended for human therapy.

ORAL VACCINE  ADMINISTRATION

Development of a microbial vaccine in the form of a lyophilized tablet for oral administration.

DIAGNOSTICS

AUMED a.s. is involved in the fight against the Covid-19 pandemic. In cooperation with Protean s.r.o. and Institute of Molecular and Translational Medicine, AUMED a.s. launched a modern diagnostics of SARS-CoV-2 virus under the name AUMED test RT-LAMP Assay SARS-CoV-2.

AUMED, a.s. launches also its own self-sampling set based on the principle of gargling of the oral cavity and pharynx.

With this step, the company significantly expands its portfolio of professional activities!

AUMED test RT-LAMP Assay SARS-CoV-2

AUMED a.s. launched a modern diagnostics of SARS-CoV-2 virus under the name AUMED test RT-LAMP Assay SARS-CoV-2.

PCR GARGLING KIT

Self-collection gargle kit for the detection of viral diseases

PHARMACEUTICAL PRODUCTION

AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a manufacturer of the STAFAL medicine, which, on the basis of bacteriophage, as an active substance, addresses one of the possible alternative ways to combat the growing resistance to antibiotics. STAFAL is a unique authorized product in the EU. The safety and effectiveness of the medicine is validated by many years of use in the medical field.

With this step, the company significantly expands its portfolio of professional activities in the field of human immunobiological issues, which is one of its thematic priorities.

STAFAL

A medicine that, based on bacteriophage, as an active substance, addresses one of the possible alternative ways to combat the growing resistance to antibiotics.

EXPERT AND ADVISORY ACTIVITIES

AUMED, a.s. focuses its professional activities on highly specific immunobiological issues.

AUMED, a.s. solves research projects in the field of bacterial vaccines (pertussis vaccine – Bordetella pertussis) and immunomodulators (transfer factor innovation).

In addition to its own research and development activities, it uses its expertise for consulting, advisory and training activities for external entities. These are highly specified pharmaceutical professional activities with an emphasis on GMP (Good Manufacturing Practice), which are actively required by external companies.

References:

Hematology and Blood Transfusion Institute – training and expert activities of AUMED a.s. personnel concerning the implementation of GMP in the area of ATMP (Advanced Therapy Medicinal Products). Consultations with SÚKL. Company audits participation.

Institutul Pasteur Romania – experts activities concerning the construction project of a new manufacturing areal for pharmaceutical manufacture.

Co Antigen Ltd, Research and Prouction Center the Republic of Kazakhstan, Almaty – expert activities concerning the implementation of GMP in pharmaceutical manufacture. Personnel training. Practical training. Representation before government authority.

EBRD – European Bank for Reconstruction and Development – AUMED a.s. personnel are registered as expert counsel to the bank in the area of pharmaceutical issues for small companies. For this purpose, they are being retained by the Bank of London for specific projects realized by the bank abroad.

ICRC (International Clinical Research Center St. Anne’s Faculty – consultancy activities for the implementation of GMP in the entire process – specifically, project participation, construction realization consultation, technological assembly implementation, validation issues, documents creation, personnel training etc.

Macromolecular Chemistry Institute AV ČR – BIOCEV department – (Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University in Vestec). Consultancy activities for the implementation of GMP in the entire process – specifically, project participation, SÚK project consultation, construction realization consultation, technological assembly implementation, validation issues, documents creation, personnel training etc.

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701, Email: info@aumed.cz
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s